A Biotech Breakthrough?
Oct 22, 2019 ·
19m 2s
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Description
Biogen rises on news that it plans to file for FDA approval of its Alzheimers drug, Aducanumab. Under Armour gets a new CEO. And Hasbro tumbles on tariff trouble. Motley...
show more
Biogen rises on news that it plans to file for FDA approval of its Alzheimers drug, Aducanumab. Under Armour gets a new CEO. And Hasbro tumbles on tariff trouble. Motley Fool analysts Andy Cross and Ron Gross tackle those stories and weigh in on the relative merits of Monopoly and Mr. Potato Head. Thanks to Molekule for supporting our channel. Get 10% off your first air purifier at http://www.molekule.com with code fool10.
show less
Information
| Author | The Motley Fool |
| Organization | The Motley Fool |
| Website | - |
| Tags |
Copyright 2026 - Spreaker Inc. an iHeartMedia Company
Comments